Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Champions Biotechnology has established an agreement with ImClone Systems for the preclinical evaluation of certain therapeutic antibodies in ImClone's clinical development pipeline.
Subscribe to our email newsletter
As part of the agreement, ImClone will utilize Champions Biotechnology’s Biomerk Tumorgrafts in the initial preclinical evaluation.
Doug Burkett, president of Champions Biotechnology, said: “Studies suggest that our Biomerk Tumorgrafts provide an accelerated and more predictive platform for the evaluation of oncology drugs. The platform also enables biomarker discovery that we expect will benefit us as we facilitate partnerships between therapeutic and diagnostic companies.”